Interim report 2026
Filed with HKEX · Stock code 1548 · · 94 pages · English
2 Corporate Profile 3 Corporate Information 5 Financial Highlights 7 Management’s Discussion and Analysis 26 Other Information 43 Independent Review Report 44 Interim Condensed Consolidated Statement of Profit or Loss 45 Interim Condensed Consolidated Statement of Comprehensive Income 46 Interim Condensed Consolidated Statement of Financial Position 48 Interim Condensed Consolidated Statement of C
Genscript Biotech Corporation on 6ix
Earlier from Genscript Biotech
- Next Day Disclosure Return
- Completion of placing of new shares under the general mandate
- GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
- GenScript Sets New Benchmark for Responsible Biotech Leadership with 2025 ESG Report
- GenScript and Mimulus Partner to Industrialize DNA-Based Data Storage for the AI Era
Later from Genscript Biotech
- Passing away of an independent non-executive director and change in composition of board committees
- List of directors and their role and function
- Announcement pursuant to rule 13.10 of the listing rules
- Change in board lot size
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Genscript Biotech into a list and get an email when it puts out news.
Follow Genscript Biotech